Tweet
New Non-Invasive Nerve Stim Procedure for Pain!
Hi,
Here is the address for a VERY! interesting video clip and a press release:
Video Clip:
http://www.chronicpainrx.com/dsp_video.cfm
Press Release:
http://biz.yahoo.com/prnews/010206/ut_dynt_ne.html
Tuesday February 6, 9:10 am Eastern Time
Press Release
SOURCE: Dynatronics Corporation
Dynatronics Introduces New Devices for Chronic Pain and Announces Preliminary Study Results for New Chronic Pain Treatment Technology
SALT LAKE CITY, Feb. 6 /PRNewswire/ -- Dynatronics Corporation (Nasdaq: DYNT - news) today announced preliminary study results for its new chronic pain treatment technology. Two devices built on the new technology -- the Dynatron STS(TM) clinical unit and the Dynatron STS Rx(TM) prescription unit for home use -- were introduced to distributors from around the world at meetings held February 2nd and 3rd in Salt Lake City, Utah.
``The initial clinical results are impressive,'' stated Joe Kleinkort, M.A., Ph.D., P.T., from Dallas, Texas, referring to a retrospective analysis of 180 chronic pain patients treated with the new technology. Sixty-four percent of the patients involved in this study reported a decrease in pain with an average improvement of 48 percent. In addition, 50 percent of all subjects were able to decrease medications, 55 percent reported an increase in daily life activity, and 49 percent reported an improvement in sleep.
``The Dynatron STS and STS Rx devices are truly revolutionary,'' said Dr. Steven Sacks, a pain specialist practicing in Beaumont, Texas, who was among the group of doctors presenting clinical results at the meetings. ``Having treated hundreds of patients with this technology, I am convinced it will improve the lives of many pain sufferers around the world.''
The devices utilize a patented non-invasive treatment known as Sympathetic Therapy(TM) that provides symptomatic relief of chronic pain. Medical professionals have used this proprietary technology to treat chronic pain associated with a variety of conditions in more than 1,000 patients who had previously experienced only marginal results with traditional pain therapy regimens.
``The Dynatron STS is a dramatic breakthrough,'' added Dr. Kleinkort. ``In fact, it is the most effective treatment I have ever used for chronic pain patients.''
``We are very pleased with the clinical results we are seeing,'' said Kelvyn H. Cullimore, Jr., president of Dynatronics. ``Additional research is currently underway to provide further validation of this treatment regimen. We look forward to announcing the results of additional studies over the next few months.''
Interest in the new devices has been tremendous, according to Larry K. Beardall, Dynatronics' executive vice president of marketing and sales.
``We anticipated this,'' said Beardall. ``The American Pain Foundation confirms that millions of people around the world suffer from chronic pain. The associated costs in the United States alone are estimated to exceed $100 billion annually. We are not surprised to see that the Dynatron STS devices are generating excitement throughout the industry -- especially as the results of our clinical research continue to validate the treatments.''
``Both devices will soon be ready to go to market,'' added Cullimore. ``We are now training our distribution network and expanding the infrastructure to support the marketing of these products. Based on the size of the market and the enthusiastic reception these devices are already receiving, we expect sales and profits to accelerate in future quarters as the technology becomes better known and more widely accepted.''
More information regarding this technology is available at http://www.dynatronics.com/.
Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets.
(This press release contains forward-looking statements. Those statements include references to the company's expectations for the outcome of clinical studies, the size of the market for the new products, anticipated growth in sales and profitability in future periods and similar statements. The reader is cautioned that actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to changes in the regulatory environment, growth in the physical medicine industry; competitive factors; availability of third party component parts and products; inventory risks due to shifts in market demand; changes in product mix; and the risk factors listed from time to time in the company's SEC reports, including, but not limited to the report on Form 10-QSB for the quarter ended September 30, 2000 and Form 10-KSB for the year ended June 30, 2000.)
SOURCE: Dynatronics Corporation
Email this story - Most-emailed articles - Most-viewed articles
--------------------------------------------------------------------------------
More Quotes and News: Dynatronics Corp (NasdaqSC
YNT - news)
Related News Categories: medical/pharmaceutical
--------------------------------------------------------------------------------
Here is the address for a VERY! interesting video clip and a press release:
Video Clip:
http://www.chronicpainrx.com/dsp_video.cfm
Press Release:
http://biz.yahoo.com/prnews/010206/ut_dynt_ne.html
Tuesday February 6, 9:10 am Eastern Time
Press Release
SOURCE: Dynatronics Corporation
Dynatronics Introduces New Devices for Chronic Pain and Announces Preliminary Study Results for New Chronic Pain Treatment Technology
SALT LAKE CITY, Feb. 6 /PRNewswire/ -- Dynatronics Corporation (Nasdaq: DYNT - news) today announced preliminary study results for its new chronic pain treatment technology. Two devices built on the new technology -- the Dynatron STS(TM) clinical unit and the Dynatron STS Rx(TM) prescription unit for home use -- were introduced to distributors from around the world at meetings held February 2nd and 3rd in Salt Lake City, Utah.
``The initial clinical results are impressive,'' stated Joe Kleinkort, M.A., Ph.D., P.T., from Dallas, Texas, referring to a retrospective analysis of 180 chronic pain patients treated with the new technology. Sixty-four percent of the patients involved in this study reported a decrease in pain with an average improvement of 48 percent. In addition, 50 percent of all subjects were able to decrease medications, 55 percent reported an increase in daily life activity, and 49 percent reported an improvement in sleep.
``The Dynatron STS and STS Rx devices are truly revolutionary,'' said Dr. Steven Sacks, a pain specialist practicing in Beaumont, Texas, who was among the group of doctors presenting clinical results at the meetings. ``Having treated hundreds of patients with this technology, I am convinced it will improve the lives of many pain sufferers around the world.''
The devices utilize a patented non-invasive treatment known as Sympathetic Therapy(TM) that provides symptomatic relief of chronic pain. Medical professionals have used this proprietary technology to treat chronic pain associated with a variety of conditions in more than 1,000 patients who had previously experienced only marginal results with traditional pain therapy regimens.
``The Dynatron STS is a dramatic breakthrough,'' added Dr. Kleinkort. ``In fact, it is the most effective treatment I have ever used for chronic pain patients.''
``We are very pleased with the clinical results we are seeing,'' said Kelvyn H. Cullimore, Jr., president of Dynatronics. ``Additional research is currently underway to provide further validation of this treatment regimen. We look forward to announcing the results of additional studies over the next few months.''
Interest in the new devices has been tremendous, according to Larry K. Beardall, Dynatronics' executive vice president of marketing and sales.
``We anticipated this,'' said Beardall. ``The American Pain Foundation confirms that millions of people around the world suffer from chronic pain. The associated costs in the United States alone are estimated to exceed $100 billion annually. We are not surprised to see that the Dynatron STS devices are generating excitement throughout the industry -- especially as the results of our clinical research continue to validate the treatments.''
``Both devices will soon be ready to go to market,'' added Cullimore. ``We are now training our distribution network and expanding the infrastructure to support the marketing of these products. Based on the size of the market and the enthusiastic reception these devices are already receiving, we expect sales and profits to accelerate in future quarters as the technology becomes better known and more widely accepted.''
More information regarding this technology is available at http://www.dynatronics.com/.
Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets.
(This press release contains forward-looking statements. Those statements include references to the company's expectations for the outcome of clinical studies, the size of the market for the new products, anticipated growth in sales and profitability in future periods and similar statements. The reader is cautioned that actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to changes in the regulatory environment, growth in the physical medicine industry; competitive factors; availability of third party component parts and products; inventory risks due to shifts in market demand; changes in product mix; and the risk factors listed from time to time in the company's SEC reports, including, but not limited to the report on Form 10-QSB for the quarter ended September 30, 2000 and Form 10-KSB for the year ended June 30, 2000.)
SOURCE: Dynatronics Corporation
Email this story - Most-emailed articles - Most-viewed articles
--------------------------------------------------------------------------------
More Quotes and News: Dynatronics Corp (NasdaqSC
YNT - news) Related News Categories: medical/pharmaceutical
--------------------------------------------------------------------------------
Comment